Compare Recursion Pharmaceuticals Inc (RXRX) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B), while iShares 20 Plus Year Treasury Bond ETF trades at $81.49. Which is the better fit depends on your goals.
| RXRX | TLT | |
|---|---|---|
Market Cap | $1.74B | — |
Sector | Health | — |
52-Week High | $6.79 | $92.06 |
52-Week Low | $2.84 | $81.35 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
TLT trades at $82.20, down slightly by 0.01% with a bearish technical signal from moving averages. The ETF faces headwinds from rising Treasury yields and potential large-scale selling by institutional investors like Norway's sovereign wealth fund. Recent Treasury buyback announcements of up to $6 billion in long-dated debt provide some support, but the overall trend remains challenging amid inflation concerns and rising oil prices.
The outlook for TLT remains cautious as rising interest rates and inflation pressures continue to weigh on long-duration bonds. While current RSI levels suggest potential oversold conditions, the fundamental environment of higher yields and potential institutional selling creates significant downside risk. Investors should monitor Treasury policy actions and global bond market developments closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
